Hepatitis B Immunization Schedule
For adults aged ≥18 years, use Heplisav-B (2 doses at 0 and 1 month) as the preferred schedule for optimal completion rates and rapid protection, or alternatively use the standard 3-dose series (Recombivax HB, Engerix-B, or PreHevbrio) at 0,1, and 6 months. 1
Standard Adult Schedules (≥18 years)
The ACIP 2022 guidelines provide multiple evidence-based options depending on vaccine type and clinical circumstances 1:
Preferred Options for General Adult Population
- Heplisav-B: 2 doses (20 μg/0.5 mL) at 0 and 1 month—this is the most convenient schedule with excellent completion rates 1
- Recombivax HB: 3 doses (10 μg/1 mL) at 0,1, and 6 months 1
- Engerix-B: 3 doses (20 μg/1 mL) at 0,1, and 6 months 1
- PreHevbrio: 3 doses (10 μg/1 mL) at 0,1, and 6 months (ACIP-recommended 2022) 1
Combination Vaccine Option
- Twinrix (HepA-HepB): Standard schedule of 3 doses at 0,1, and 6 months, OR accelerated schedule of 4 doses at 0 days, 7 days, 21-30 days, and 12 months 1
Adolescent Schedules (11-19 years)
- Ages 11-15 years: Recombivax HB offers a 2-dose option (10 μg/0.5 mL) at 0 and 4-6 months, OR standard 3-dose series at 0,1, and 6 months 1
- Important caveat: If the adolescent turns 16 before receiving the second dose, switch to the 3-dose series with pediatric formulation 1
- Ages 11-19 years: Engerix-B 3 doses (10 μg/0.5 mL) at 0,1, and 6 months 1
Special Populations
Immunocompromised Adults and Hemodialysis Patients (≥20 years)
These patients require higher doses and modified schedules 1:
- Recombivax HB: 40 μg (1 mL) given as 3 doses at 0,1, and 6 months 1
- Engerix-B: 40 μg (2 mL total—given as single 2-mL dose or two 1-mL doses) as 4 doses at 0,1,2, and 6 months 1
- Critical limitation: Heplisav-B and PreHevbrio have NOT been established as safe or effective in hemodialysis patients—do not use these formulations 1
Pregnant Women
Use only Engerix-B, Recombivax HB, or Twinrix for pregnant women needing HepB vaccination 1. Data on Heplisav-B and PreHevbrio are insufficient to inform vaccine-associated risks in pregnancy 1.
Managing Interrupted Schedules
A major practical advantage: the series never needs to be restarted if interrupted 1. Follow these minimum intervals:
- Between doses 1 and 2: Minimum 4 weeks 1
- Between doses 2 and 3: Minimum 8 weeks 1
- Between doses 1 and 3: Minimum 16 weeks 1
If interrupted after dose 1, give dose 2 as soon as possible, then ensure doses 2 and 3 are separated by ≥8 weeks 1. If only dose 3 is delayed, administer it as soon as possible 1.
Grace period: Doses given ≤4 days before the minimum interval are considered valid 1. However, this 4-day grace period does NOT apply to the first 3 doses of Twinrix when using the accelerated schedule 1.
Key Clinical Considerations
Pre-vaccination Testing
Testing for HBsAg, anti-HBs, and anti-HBc can identify those already immune or infected, but lack of access to serologic testing should never be a barrier to vaccination—proceed with vaccination if testing is not feasible 1.
Vaccine Interchangeability
Different manufacturers' vaccines can be used interchangeably to complete the series without repeating doses, though using the same brand throughout is preferable when feasible 1.
Post-vaccination Serologic Testing
Routine post-vaccination testing is NOT recommended for most patients 1. However, specific groups require testing 1-2 months after series completion 1:
- Healthcare personnel and public safety workers
- Hemodialysis patients
- Immunocompromised persons
- Infants born to HBsAg-positive mothers
Booster Dose Considerations
For hemodialysis patients, assess need for boosters through annual anti-HBs testing; administer booster when levels decline to <10 mIU/mL 1. For other immunocompromised persons with ongoing exposure risk, consider annual testing and boosters 1.
Evidence on Alternative Schedules
Research supports flexibility in scheduling when standard intervals are impractical. Studies demonstrate that longer intervals between doses (e.g., 0,12, and 24 months) produce excellent immunogenicity 2, and accelerated schedules (0,1,2 months with booster at 12 months) provide more rapid seroconversion 3, 4, 5. However, the final dose timing significantly impacts antibody levels—longer intervals between the second and third doses result in higher geometric mean titers and likely better long-term protection 5.